Key result
Clofibrate (2 g daily) normalized platelet sensitivity to ADP and improved sensitivity to epinephrine and collagen in patients with familial hyperbetalipoproteinemia compared to untreated patients.
Why the study?
Does clofibrate reduce platelet hypersensitivity to aggregation in patients with familial hyperbetalipoproteinemia?
Population
29 patients with familial hyperbetalipoproteinemia and 26 normal subjects.
Comparison
Clofibrate 2 g daily vs Untreated patients with familial…
Design
Cohort
Authors
Loading...
Clofibrate may normalize platelet sensitivity independent of lipids in familial hyperbetalipoproteinemia; hypothesis-generating and should not yet change practice.
Observational (n=55)
Does clofibrate reduce platelet hypersensitivity to aggregation in patients with familial hyperbetalipoproteinemia?
Clofibrate reduces platelet hypersensitivity to aggregation in patients with familial hyperbetalipoproteinemia, independent of its lipid-lowering effects, which may decrease thrombotic complications of atherosclerosis.
Carvalho et al. (1974) conducted an observational in Familial hyperbetalipoproteinemia (n=55). Clofibrate vs. Untreated patients and normal subjects was evaluated on Platelet sensitivity to aggregation (ADP, epinephrine, and collagen). Clofibrate (2 g daily) normalized platelet sensitivity to ADP and improved sensitivity to epinephrine and collagen in patients with familial hyperbetalipoproteinemia compared to untreated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: